Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$5.05 USD
+0.05 (1.00%)
Updated May 29, 2024 03:59 PM ET
After-Market: $5.07 +0.02 (0.40%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Syros Pharmaceuticals, Inc. [SYRS]
Reports for Purchase
Showing records 161 - 180 ( 221 total )
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
AML Data Looks Good; Reiterate Buy - Raising PT to $14
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -New Leukemia Approvals - Their Implications
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SY-1365 Hints at Clinical Efficacy in Early Study
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts Around SY-1365 Phase 1 Dose Escalation Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2018 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CORRECTED: ASH 2018 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Highlighting CDK7 and Valuation; Upgrading to Buy - Maintaining $12 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q18: Early Data Around the Corner at the Triple and ASH Meetings
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Dissecting 2H18; Maintain Neutral - Lowering PT to $12
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
2Q, Awaiting 4Q Data Readout to Drive a Recovery
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
A Closer Look at the Expansion Cohorts in SY-1365 Phase 1 Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
1Q18 Financials; Looking Ahead to Key SY-1365 and SY-1425 Updates in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.